Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value

J. Marková, C. Kobe, M. Skopalová, K. Klásková, K. Dědečková, A. Plütschow, H.T. Eich, M. Dietlein, A. Engert, T. Kozák

. 2009 ; 20 (7) : 1270-1274.

Language English Country Great Britain

Document type Clinical Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc11019624

Grant support
NR8033 MZ0 CEP Register

BACKGROUND: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) in patients with advanced-stage HL. PATIENTS AND METHODS: From January 2004 to March 2007, 50 patients with newly diagnosed HL in clinical stages IIB with large mediastinal mass or extranodal disease, III and IV were treated according to the HD15 protocol of the German Hodgkin Study Group. All patients received a PET scan after four cycles of BEACOPP (PET-4). RESULTS: Of the overall group, 14 of 50 patients had a positive PET-4 while 36 had a negative PET-4. At a median observation time of 25 months, 2 of the 14 patients with a positive PET-4 had progressed or relapsed, while there was no progression or relapse in PET-4-negative patients. CONCLUSION: Our results indicate a very good negative predictive value of PET-4 in advanced-stage HL patients treated with BEACOPP.

References provided by Crossref.org

000      
03640naa 2200625 a 4500
001      
bmc11019624
003      
CZ-PrNML
005      
20221005142203.0
008      
110714s2009 xxk e eng||
009      
AR
024    7_
$a 10.1093/annonc/mdn768 $2 doi
035    __
$a (PubMed)19228806
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Marková, Jana $7 xx0143313
245    10
$a FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value / $c J. Marková, C. Kobe, M. Skopalová, K. Klásková, K. Dědečková, A. Plütschow, H.T. Eich, M. Dietlein, A. Engert, T. Kozák
314    __
$a Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic. markova@fnkv.cz
520    9_
$a BACKGROUND: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) in patients with advanced-stage HL. PATIENTS AND METHODS: From January 2004 to March 2007, 50 patients with newly diagnosed HL in clinical stages IIB with large mediastinal mass or extranodal disease, III and IV were treated according to the HD15 protocol of the German Hodgkin Study Group. All patients received a PET scan after four cycles of BEACOPP (PET-4). RESULTS: Of the overall group, 14 of 50 patients had a positive PET-4 while 36 had a negative PET-4. At a median observation time of 25 months, 2 of the 14 patients with a positive PET-4 had progressed or relapsed, while there was no progression or relapse in PET-4-negative patients. CONCLUSION: Our results indicate a very good negative predictive value of PET-4 in advanced-stage HL patients treated with BEACOPP.
590    __
$a bohemika - dle Pubmed
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x terapeutické užití $7 D000971
650    _2
$a bleomycin $x aplikace a dávkování $7 D001761
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a progrese nemoci $7 D018450
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a etoposid $x aplikace a dávkování $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorodeoxyglukosa F18 $x aplikace a dávkování $7 D019788
650    _2
$a Hodgkinova nemoc $x farmakoterapie $x radioizotopová diagnostika $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pozitronová emisní tomografie $x metody $7 D049268
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a prokarbazin $x aplikace a dávkování $7 D011344
650    _2
$a prognóza $7 D011379
650    _2
$a radiofarmaka $x aplikace a dávkování $7 D019275
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kobe, C.
700    1_
$a Skopalová, Magdaléna $7 xx0137935
700    1_
$a Klásková, Kateřina. $7 _AN051492
700    1_
$a Dědečková, Kateřina $7 xx0063670
700    1_
$a Plütschow, A.
700    1_
$a Eich, H.T.
700    1_
$a Dietlein, M.
700    1_
$a Engert, A.
700    1_
$a Kozák, Tomáš, $d 1963- $7 xx0021767
773    0_
$t Annals of Oncology $w MED00000432 $g Roč. 20, č. 7 (2009), s. 1270-1274
856    41
$u https://doi.org/10.1093/annonc/mdn768 $y plný text volně přístupný
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110715114655 $b ABA008
991    __
$a 20221005142158 $b ABA008
999    __
$a ok $b bmc $g 864482 $s 729502
BAS    __
$a 3
BMC    __
$a 2009 $x MED00000432 $b 20 $c 7 $d 1270-1274 $m Annals of oncology $n Ann Oncol
GRA    __
$a NR8033 $p MZ0
LZP    __
$a 2011-3B09/Bjvme

Find record

Citation metrics